SGLT2 Inhibitors Lower NAFLD, HCC Risks Over DPP4i

Sodium glucose cotransporter 2 inhibitors (SGLT2is) lowered the risk of nonalcoholic fatty liver disease and hapatocellular carcinoma versus dipeptidyl-peptidase-4 inhibitors (DPP4is).
First Look